Compared with vaccines based on inactivated virus or recombinant proteins, peptide based vaccine has many advantages,such as wider coverage, lower cost and higher production quality control. Besides medical uses, high-quality low-cost prophylactic and therapeutic vaccines have important social and economic roles in a highly populated country such as China. 

Domestic and foreign research institutes and pharmaceutical companies have spent great effort in developing peptide based vaccines. Recently, Duke University‘s Phase II results from a peptide based vaccine for brain tumors has demonstrated the potential of such therapeutic peptide vaccines in treating serious diseases such as cancer.

ImmuOn Therapeutics is currently working closely with China Pharmaceutical University and other research institutes to develop various anti-viral, anti-cancer peptide and peptide-protein fusion vaccines.